Akeso shares rise as cancer drug candidate enters clinical trials
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump sees ’very bad’ future for NATO if allies do not help in Iran- FT interview Oil spike may trim global GDP by 0.3%, push inflation higher: Goldman Asia shares cautious, oil gains on Hormuz doubts US Economy: $100 oil triggers a dual-edged sword for domestic growth 🧠 Upgrade to AI Insights (South Africa Philippines Nigeria) 🧠 Upgrade to AI Insights Akeso shares rise as cancer drug candidate enters clinical trials By Author Ayushman Ojha Stock Markets Published 03/16/2026, 01:32 AM Akeso shares rise as cancer drug candidate enters clinical trials 0 9926 5.99% Investing.com-- Shares of Hong Kong-listed biotech firm Akeso (HK:9926) rose on Monday after the company said a new cancer drug candidate had received regulatory clearance to begin clinical testing, marking a milestone in its immunotherapy pipeline. Akeso said its experimental trispecific antibody AK150 has received Investigational New Drug clearance from China’s National Medical Products Administration to start clinical trials in patients with advanced solid tumors. Shares of the company jumped 6% to HK$117 as of 05:29 GMT. Get real-time updates on stock market news with InvestingPro The drug is designed to simultaneously target ILT2, ILT4, and CSF1R, making it the only trispecific antibody globally under development against those three targets, according to the company. The company said the drug was developed using its proprietary Tetrabody multispecific antibody platform and an AI-driven drug discovery system. AK150 becomes Akeso’s first trispecific antibody candidate to enter clinical-stage development, adding to the firm’s broader oncology pipeline of multispecific antibody therapies targeting difficult-to-treat cancers such as lung, liver, and pancreatic tumors.
Read full article at source